KLHDC4: A Potential Drug Target and Biomarker (G54758)

Target Name: KLHDC4

NCBI ID: G54758

KLHDC4

KLHDC4: A Potential Drug Target and Biomarker

Kallikrein-related peptidases (KLHPs) are a family of enzymes that belong to the serine proteases superfamily 11. These enzymes are involved in the regulation of extracellular matrix (ECM) components, including collagen, laminin, and heparin. KLHPs have been implicated in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. In this article, we will discuss the potential drug target and biomarker KLHDC4 and its clinical implications.

KLHDC4: Structure and Function

KLHDC4 is a 17-kDa serine protease that is expressed in various tissues, including liver, pancreas, and heart. It is localized to the cytoplasm and has been shown to be involved in the degradation of ECM components. KLHDC4 has two distinct forms, KLHDC4-long and KLHDC4-short, which differ in their catalytic activity. KLHDC4-long is predominantly found in the cytoplasm and is involved in the degradation of collagen, while KLHDC4-short is predominantly found in the endoplasmic reticulum and is involved in the degradation of laminin and heparin.

KLHDC4 has been shown to be involved in various physiological processes, including cell signaling, tissue repair, and inflammation. For example, KLHDC4 has been shown to be involved in the regulation of T cell responses and has been implicated in the development of autoimmune disorders. Additionally, KLHDC4 has been shown to be involved in the regulation of cell migration and has been implicated in the development of cancer.

Drug Targeting

KLHDC4 has been identified as a potential drug target due to its involvement in various diseases. The inhibition of KLHDC4 has been shown to be effective in treating various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

In cancer, KLHDC4 has been shown to be involved in the regulation of cell signaling and has been implicated in the development of various types of cancer. For example, KLHDC4 has been shown to be involved in the regulation of theNotch signaling pathway, which is involved in the development of neurodegenerative diseases. Additionally, KLHDC4 has been shown to be involved in the regulation of the TGF-β pathway, which is involved in the development of various types of cancer.

In neurodegenerative diseases, KLHDC4 has been shown to be involved in the regulation of neurotrophic factors, which are important for the maintenance of neural function. For example, KLHDC4 has been shown to be involved in the regulation of brain-derived neurotrophic factor (BDNF), which is an important neurotrophic factor that is involved in the development and maintenance of neural function.

In autoimmune disorders, KLHDC4 has been shown to be involved in the regulation of immune cell function and has been implicated in the development of autoimmune disorders. For example, KLHDC4 has been shown to be involved in the regulation of the development and function of immune cells, including T cells and B cells.

Biomarker

KLHDC4 has also been shown to be potential biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. For example, KLHDC4 has been shown to be involved in the regulation of cancer cell proliferation and has been used as a biomarker for the treatment of various types of cancer. Additionally, KLHDC4 has

Protein Name: Kelch Domain Containing 4

The "KLHDC4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KLHDC4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets